Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Alector

Request full access

Combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel

San Francisco, United StatesFounded 2013Biotech & Life Sciences

About Alector

Alector is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company operates in the healthcare and biotechnology market, targeting a critical and growing need for effective treatments in this area. Alector's primary clients include healthcare providers, research institutions, and pharmaceutical companies that are involved in the treatment and study of neurodegenerative conditions.

Alector's business model revolves around research and development (R&D) of novel therapeutic candidates. The company leverages insights from immunology, neurology, and human genetics to create medicines that harness the body's innate ability to heal itself. By focusing on early-stage clinical trials and gathering disease-specific data quickly, Alector aims to increase the probability of success for its therapies.

The company makes money through a combination of funding from partnerships, grants, and potential future revenues from the commercialization of its therapies. Alector's strategy includes presenting its findings at healthcare conferences and publishing data from clinical trials to attract investment and collaboration opportunities.

In summary, Alector is pioneering new treatments for neurodegenerative diseases by combining cutting-edge science with a strategic approach to drug development. Their innovative pipeline and commitment to addressing unmet medical needs position them as a key player in the biopharmaceutical industry.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2019

Alector in the San Francisco ecosystem

Live from Dealroom

The Alector office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

18 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Series B and later16 investors entered at this stage

Employees mapped 139 incl. 3 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$91M

63 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Alector on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.